- $48.67m
- $129.31m
- $83.81m
Gene therapy makers set to end 2024 in the red
Brief: Bluebird Bio Announces 1-For-20 Reverse Stock Split
CMS enters agreement with Vertex, bluebird to improve access to gene therapies (updated)
CMS enters agreement with Vertex, bluebird to improve access to gene therapies
Brief: bluebird bio Confirms Participation in Center for Medicare and Medicaid Innovation (CMMI) Cell and Gene Therapy Access Model
Bluebird falls as FDA weighs cancer risks of co's gene therapy
FDA probes blood cancer risk from bluebird's gene therapy, weighs regulatory action (updated)
FDA investigates risk of blood cancers from bluebird bio's gene therapy
Brief: FDA Investigating Serious Risk Of Hematologic Malignancy Following Skysona (Elivaldogene Autotemcel)
Bluebird down after Q3 revenue misses estimates, BofA cuts rating
U.S. RESEARCH ROUNDUP- Applied Materials, Disney, Walmart
bluebird bio Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: Bluebird Bio Q3 EPS USD -0.31
bluebird bio Inc expected to post a loss of 36 cents a share - Earnings Preview
Beam Therapeutics falls after patient death in early trial
bluebird bio Inc expected to post a loss of 36 cents a share - Earnings Preview
Insight: Why gene therapy for sickle cell is slow to catch on with patients
U.S. STOCKS ON THE MOVE-Copper miners, Visa, Bluebird bio
Bluebird bio rises after cutting 25% workforce to reduce costs